Payment overview · 2025
General Payments
$955.72
55 reported records · 16 companies
Healthcare provider profile · identity verified
Patsy Buccino, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GIRARD, OH · NPI 1982673232
Verified facts
What the public records show
CMS Open Payments records show Patsy Buccino, D.O. received $955.72 in general payments during 2025 across 55 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $212.22 | 22.2% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $189.06 | 19.8% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.13 | 15.4% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $72.24 | 7.6% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $59.33 | 6.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.89 | 4.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.81 | 4.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.84 | 3.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $28.41 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.68 | 2.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.09 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.55 | 1.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.22 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.96 | 1.8% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $14.72 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.57 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $955.72 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $189.06 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $159.03 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $147.13 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $147.13 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $130.02 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.77 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $78.97 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $72.24 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $45.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| ELAPRASE Normalized: elaprase |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 275 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
275 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
275 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 704 | 186 |
| Amlodipine Besylate | Amlodipine Besylate | 560 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 521 | 123 |
| Lisinopril | Lisinopril | 436 | 117 |
| Metformin Hcl | Metformin Hcl | 372 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 98 |
| Eliquis | Apixaban | 275 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 53 |
| Simvastatin | Simvastatin | 187 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 180 | 23 |
| Carvedilol | Carvedilol | 172 | 47 |
| Omeprazole | Omeprazole | 162 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 39 |
| Tramadol Hcl | Tramadol Hcl | 153 | 37 |
| Azithromycin | Azithromycin | 148 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 20 |
| Furosemide | Furosemide | 131 | 45 |
| Glipizide Er | Glipizide | 126 | 33 |
| Losartan Potassium | Losartan Potassium | 123 | 31 |
| Gabapentin | Gabapentin | 119 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 35 |
| Allopurinol | Allopurinol | 100 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 29 |
| Ozempic | Semaglutide | 99 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 31 |
| Sertraline Hcl | Sertraline Hcl | 92 | 25 |
| Ezetimibe | Ezetimibe | 88 | 26 |
| Methylprednisolone | Methylprednisolone | 86 | 69 |
| Synthroid | Levothyroxine Sodium | 86 | 23 |
| Potassium Chloride | Potassium Chloride | 85 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 84 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 24 |
| Lorazepam | Lorazepam | 76 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 73 | 20 |
| Clonazepam | Clonazepam | 71 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 20 |
| Jardiance | Empagliflozin | 67 | 18 |
| Mirtazapine | Mirtazapine | 65 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 17 |
| Diazepam | Diazepam | 56 | suppressed |
| Irbesartan | Irbesartan | 56 | 11 |
| Meloxicam | Meloxicam | 55 | 20 |
| Metformin Hcl Er | Metformin Hcl | 55 | 15 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Atenolol | Atenolol | 53 | 14 |
| Warfarin Sodium | Warfarin Sodium | 53 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 17 |
| Montelukast Sodium | Montelukast Sodium | 51 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 12 |
| Trazodone Hcl | Trazodone Hcl | 50 | 15 |
| Bupropion Xl | Bupropion Hcl | 49 | 14 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Valsartan | Valsartan | 46 | 11 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 12 |
| Finasteride | Finasteride | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 18 |
| Spironolactone | Spironolactone | 39 | 12 |
| Baclofen | Baclofen | 38 | 13 |
| Glimepiride | Glimepiride | 38 | suppressed |
| Glipizide | Glipizide | 38 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Dexilant | Dexlansoprazole | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $955.72 · 55 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, ELAPRASE, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, Korlym, MOUNJARO, NURTEC ODT, QSYMIA, QULIPTA, REXULTI, UBRELVY, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error